Literature DB >> 17154676

A Cross-Sectional Comparison of Direct Medical Care Costs among COPD and Asthma Patients Living in the Community in Northern Ireland.

Eoin Murtagh1, Ciaran O'neill, Denise McAllister, Frank Kee, Joe Macmahon, Liam G Heaney.   

Abstract

INTRODUCTION: Asthma and COPD are known to have significant health and economic consequences. Little is known about the costs of the latter in the UK. In this study we report the results of a comparison of the direct medical costs associated with COPD and asthma, where diagnoses are based on a robust prevalence study of a random sample of the Northern Ireland population.
METHODS: A two-stage survey was used to identify individuals with COPD and asthma. The diagnoses of asthma and COPD were based on patient history and lung function. Patients completed a detailed questionnaire covering healthcare utilization over the past 12 months, socioeconomic characteristics, impact of the disease on quality of life, and activities of daily living.
RESULTS: Forty-nine patients were diagnosed with COPD and 57 with asthma. Three asthma patients were excluded from the main analysis because they were thought to have atypical inpatient stays or other resource use. The mean direct healthcare cost for each COPD patient was estimated at pound171.69 ($US309; year 2000 value) per annum, significantly less than the average cost of asthma among the 54 analyzed of pound544.54 ($US980) [p < 0.05]. A correlation analysis revealed that among COPD patients, disease severity, defined by lung function, was a significant predictor of costs.
CONCLUSION: Community-based costs for asthma are greater than those for COPD; this may relate in part to a relative under-diagnosis of COPD (73.5% COPD vs 15.8% asthma). As anticipated, the cost of COPD increases as FEV(1) decreases. Further analysis will enable modeling of the cost consequences of both increased diagnosis and better management of COPD.

Entities:  

Mesh:

Year:  2006        PMID: 17154676     DOI: 10.2165/00151829-200605060-00012

Source DB:  PubMed          Journal:  Treat Respir Med        ISSN: 1176-3450


  3 in total

Review 1.  Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease.

Authors:  Kunal Srivastava; Deepika Thakur; Sheetal Sharma; Yogesh Suresh Punekar
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

2.  Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England.

Authors:  Leah B Sansbury; David A Lipson; Chanchal Bains; Glenn A Anley; Kieran J Rothnie; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-03-03

3.  Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.

Authors:  Yogesh Suresh Punekar; Sarah H Landis; Keele Wurst; Hoa Le
Journal:  Respir Res       Date:  2015-11-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.